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The IL1RL1 (ST2) gene locus is robustly associated with asthma; however, the contribution of 
single nucleotide polymorphisms (SNPs) in this locus to specific asthma subtypes and the 
functional mechanisms underlying these associations remain to be defined. We tested for 
association between IL1RL1 region SNPs and characteristics of asthma as defined by clinical 
and immunological measures and addressed functional effects of these genetic variants in 
lung tissue and airway epithelium. Utilizing 4 independent cohorts (Lifelines, Dutch Asthma 
GWAS [DAG], Genetics of Asthma Severity and Phenotypes [GASP], and Manchester Asthma 
and Allergy Study [MAAS]) and resequencing data, we identified 3 key signals associated with 
asthma features. Investigations in lung tissue and primary bronchial epithelial cells identified 
context-dependent relationships between the signals and IL1RL1 mRNA and soluble protein 
expression. This was also observed for asthma-associated IL1RL1 nonsynonymous coding TIR 
domain SNPs. Bronchial epithelial cell cultures from asthma patients, exposed to exacerbation-
relevant stimulations, revealed modulatory effects for all 4 signals on IL1RL1 mRNA and/
or protein expression, suggesting SNP-environment interactions. The IL1RL1 TIR signaling 
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Introduction
Asthma is a chronic airway disorder characterized by inflammation and widespread variable airflow 
obstruction that is often reversible, either spontaneously or with treatment (1). Over the years, a signif-
icant genetic component to asthma has been identified, and today, over 130 single nucleotide polymor-
phisms (SNPs) have been reported to be associated with asthma and allergic disease in genome-wide 
association studies (GWAS) (2–4). One of  the most replicated asthma-associated genetic signals is 
the chromosome 2q12 locus, containing the IL-1 receptor like 1 (IL1RL1), IL18R1, and IL-18 recep-
tor accessory protein (IL18RAP) genes (3, 5–7). IL1RL1 is predominantly expressed as 2 major splice 
variants, one of  which contains the transmembrane domain encoding the membrane bound receptor 
(ST2L, IL1RL1-b) that facilitates signal transduction through a Toll–IL-1 receptor (TIR) domain by 
interacting with/binding to IL-1 receptor accessory protein (IL1RAP). This IL-33 receptor is expressed 
on a number of  different cell types relevant to asthma, including inflammatory cells such as T-lympho-
cytes, innate lymphoid cells, basophils, eosinophils, and mast cells, as well as structural cells such as 
fibroblasts, endothelial cells, and epithelial cells (8, 9). The other main splice variant encodes the sol-
uble form of  the receptor (sST2, IL1RL1-a), which has been detected in both bronchoalveolar lavage 
fluid and serum in asthma patients. This splice variant is hypothesized to act as a decoy receptor for its 
ligand, dampening IL-33 activity (10, 11).
The presence of  multiple polymorphisms in the IL1RL1 locus that independently contribute to 
asthma risk complicates the interpretation of  the association signal with the disease (4, 12). Because 
asthma is known to be a multifactorial and heterogeneous disease (1), we hypothesize that different 
SNPs within the IL1RL1 locus drive different subtypes or components of  asthma via independent and 
overlapping functional effects. Disease-associated SNPs may exert their functional effects by changing 
the protein sequence and/or by affecting levels of  gene transcription (expression quantitative trait locus; 
eQTL). Whereas some SNPs affect gene expression under constitutive conditions (constitutive eQTL), 
it has recently been shown that the effect of  a SNP on gene transcription is sometimes observed only in 
a specific context, such as diseased conditions (inducible eQTL) (13). We hypothesize that the genetic 
heterogeneity of  the IL1RL1 locus may be partly due to inducible eQTLs that affect gene transcription 
in asthma patients but not in healthy controls.
In this study, we set out to extend the association of  the IL1RL1 region polymorphisms with asth-
ma diagnosis and to define the relative contribution of  SNPs spanning the association signal to char-
acteristics of  asthma defined by clinical and immunological measures. To investigate these hypotheses, 
we used a step-wise study approach ultimately prioritizing selected association signals for functional 
characterization (Figure 1). Following detection of  known common variation in the locus, we identi-
fied coding and noncoding variation through resequencing of  the IL1RL1 locus in 2 European popu-
lations of  asthma patients in order to provide improved understanding of  the genetic variation in the 
IL1RL1 region. We subsequently related these SNPs to different asthma subtypes in order to identify 
key priority SNPs for functional investigation. We tested the presence of  specific eQTLs in the lung 
and bronchial epithelium, with a focus on IL1RL1 regulation, and we assessed their role in regulating 
epithelial IL1RL1 expression after stimulation with known asthma factors implicated in disease exacer-
bation, such as human rhinovirus 16 (RV-16), a known modulator of  IL-33 expression (14); European 
house dust mite (HDM) extract; and in an artificially IL-33 rich environment. Finally, we performed 
reductionist functional studies to address the effect of  coding SNPs in IL1RL1 on IL-33–induced signal 
transduction. In the same system, we investigated the effect of  IL1RL1 coding SNPs on TLR-2 and 
-4 signaling, both of  which have previously been linked to IL1RL1-TLR crosstalk in the context of  
tolerance (15, 16).
domain haplotype affected IL-33–driven NF-κB signaling, while not interfering with TLR 
signaling. In summary, we identify that IL1RL1 genetic signals potentially contribute to severe 
and eosinophilic phenotypes in asthma, as well as provide initial mechanistic insight, including 
genetic regulation of IL1RL1 isoform expression and receptor signaling.
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Results
Demographics. For details of  all cohorts used in this study, see Supplemental Methods (supplemental mate-
rial available online with this article; https://doi.org/10.1172/jci.insight.132446DS1).
Resequencing of  the IL1RL1 region. Resequencing of  the chromosome 2 region containing IL1RL1 in 200 
pooled severe asthma patient DNA samples (Genetics of  Asthma Severity and Phenotypes [GASP]) and 200 
pooled nonasthmatic, nonallergic subject DNA samples (Nottingham Gedling Cohort) identified a total of  
4107 variants, of  which 1899 were designated as valid variant calls (Supplemental Table 1). Case/control 
analysis for severe asthma using sequencing allele counts identified 8 variants of  interest in severe asthma 
through meeting criteria of  FDR < 0.05, with 3 variants surviving quality control (Supplemental Table 2).
Exon resequencing of  the IL1RL1 gene in an additional 95 asthma patients (Dutch Asthma GWAS 
[DAG]), carried out to increase our pool of  sequenced asthma patients, identified a total of  56 variants 
covering the gene’s distal and proximal promoter, introns, and exons (Supplemental Table 3).
Identification of  genetic variants associated with subphenotypes of  asthma. Considering the genomic region 
400 kb up- and downstream of  IL1RL1 (GRCh37 chr2: 102,527,961–103,368,497) that encompasses all 
known genetic signals associated with asthma (Supplemental Figure 1), we identified association between 
3 SNPs and severe asthma (resequencing analyses; Supplemental Table 2), 130 SNPs and asthma (Life-
lines cohort; Supplemental Table 4), 316 SNPs and blood eosinophil levels in a general population (Life-
lines; Supplemental Table 5), 4 SNPs and atopy (DAG/GASP; Supplemental Table 6), and 3 SNPs and 
lung function (forced expiratory volume in the first second [FEV1], DAG/GASP; Supplemental Table 7). 
Figure 1. Flow diagram of different stages of investigation carried out in this study. DAG, Dutch Asthma GWAS; 
ENCODE, Encyclopaedia of DNA Elements; GASP, Genetics of Asthma Severity and Phenotypes; LD, linkage disequilib-
rium; MAAS, Manchester Asthma and Allergy Study; NORM, Study to Obtain Normal Values of Inflammatory Variables 
From Healthy Subjects; SNP, single nucleotide polymorphism.
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We did not observe significant associations with lung function (FEV1 and FEV1/forced vital capacity 
[FVC]) in Lifelines and Manchester Asthma and Allergy Study (MAAS), nor with blood eosinophils, 
childhood onset asthma, total IgE levels, or lung function ratio (FEV1/FVC) in GASP/DAG.
We selected 4 signals of  association for further functional study by considering (a) significant associa-
tions (FDR < 0.05) with asthma subtypes in our genetic association analysis, (b) a minor allele frequency > 
0.1 to facilitate subsequent in vitro analysis, (c) independence based on r2 < 0.1 in the 1000 genomes EUR 
population (17), and (d) SNPs that were known to have a functional effect on IL1RL1 receptor signaling 
(Figure 1). A detailed description of  the SNP selection procedure can be found in the Supplemental Meth-
ods. The 3 tagging SNPs for the associated signals presented in this manuscript (Signal A: rs12474258, 
minor allele frequency [MAF]: 0.40, Asthma (T) OR: 1.20, FDR: 0.049, blood eosinophils (T) β: 0.03, 
FDR: 0.017; Signal B: rs4142132, MAF = 0.49, FEV1 (A) β: –0.07, FDR: 0.029; and Signal C: rs72825929, 
MAF = 0.10, Severe Asthma (A) χ2 statistic: 16.4, FDR: 0.035) span the IL1RL1 region (Figure 2) and 
demonstrate association with severe, eosinophilic asthma subtypes (Table 1). For convenience, we will refer 
in this paper to the signals tagged by these 3 SNPs as Signal A, Signal B, and Signal C. We also included 
the previously reported IL1RL1 TIR homology domain coding region variant tagged by rs10192157 (12), 
referred to as Signal D, for downstream analysis due to its structural changes (Ala433Thr/Gln501Arg/
Thr549Ile/Leu551Ser) known to affect/modulate IL1RL1 receptor signaling (18).
Linkage disequilibrium between selected signals and known asthma signals. We identified that, of  our 3 select-
ed signals (discounting Signal D, [rs10192157], which was selected as a functional variant based on lit-
erature), in the 1000 Genomes EUR population, only Signal B (rs4142132) is in linkage disequilibrium 
(LD) with a previously reported asthma association signal (LD r2 > 0.5; Supplemental Figure 2). Signal B 
includes reported asthma SNPs (rs11685480 [r2 = 1 with rs4142132], rs12479210 [r2 = 0.54], and rs1420101 
[r2 = 0.52]). Our remaining selected signals (rs12474258 and rs72825929) show low LD (r2 = 0.1), with 
SNPs previously associated with asthma diagnosis. For a full visualization of  the LD patterns to our 3 
selected SNPs, refer to Supplemental Figure 2.
Association testing of  previously reported asthma signals with asthma subphenotypes in our cohorts. A literature 
search identified 42 studies highlighting 19 reported SNPs associated with asthma (Supplemental Table 
8). Based on r2 < 0.1, these associations represent a single, independent signal. We were able to replicate 
association with asthma diagnosis in the Lifelines cohort for 2 known asthma-associated SNPs rs13431828 
(OR: 1.36, FDR: 0.040) (19–21) and rs10173081 (OR: 1.36, FDR: 0.040) (6, 22), which represent the same 
genetic signal (r2 = 1, 1000 Genomes EUR population). The reported asthma risk alleles for rs13431828 (C) 
and rs10173081 (C) are consistent with the rs12474258 risk allele (C) identified in the current study (i.e., 
our signal shows the same direction of  effect). We did not observe any additional association with these 19 
reported SNPs to any of  the phenotypes tested in any cohort (FDR < 0.05). Investigation to see if  the 19 
asthma SNPs also associate to blood eosinophil levels in both our cohorts and the literature; we identified a 
degree of  overlap, confirming the association of  Signal A (with which the overlapping SNPs are associated) 
with asthma and blood eosinophil levels (Supplemental Table 8).
Selected signals act as eQTLs for membrane and soluble IL1RL1 encoding transcripts in lung tissue. To assess 
functional consequences of  the selected signals, we first performed an eQTL analysis in lung tissue utiliz-
ing array data with IL1RL1 isoform–specific probes. We find that 3 of  the 4 signals (Signals B, C, and D 
tagged by rs142008 [proxy for rs4142132], rs11690532 [proxy for rs72825929], and rs10192157, respective-
ly; Table 2) act as eQTLs for IL1RL1 in whole lung tissue (Table 3). The FEV1 risk allele for Signal B (proxy 
rs1420088 [C] allele) was shown to be associated with attenuated levels of  IL1RL1 mRNA of  isoforms 
encoding both the soluble (IL1RL1-a) and transmembrane (IL1RL1-b) protein. The asthma risk allele for 
Signal C (proxy rs11690532 [C]), however, was associated with elevated IL1RL1 mRNA expression (of  
both transcripts in a combined and independent assay). The asthma risk allele for Signal D (rs10192157 
[C]) was associated with lower expression of  the transcript encoding the soluble isoform but did not show 
association with the transcript encoding the transmembrane protein. In summary, these data show that 
3 of  our prioritized signals are eQTLs for IL1RL1 in lung tissue; however, the 2 asthma-associated risk 
alleles have opposite directions of  effect on IL1RL1 mRNA expression in lung tissue. Interestingly, Signal 
A — associated with asthma and blood eosinophils — did not demonstrate any IL1RL1 eQTL association 
in lung tissue. The strongest effect estimate was observed with the IL1RL1 isoform encoding the soluble 
protein, showing a 10-fold increase over the transmembrane isoform in the presence of  the respective risk 
alleles of  Signals B and C (rs1420088 and rs11690532; Table 3).
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Association between IL1RL1 SNPs and baseline IL1RL1 expression in cultured bronchial epithelial cells from 
asthma patients. To determine the effect of  the 4 signals on IL1RL1 expression in cultured bronchial epithe-
lial cells (BECs), we examined the effect of  SNPs on baseline expression of  IL1RL1 mRNA isoforms and 
soluble IL1RL1 (IL1RL1-a) protein in human BECs (HBECs) isolated from asthma patient donors and 
cultured in vitro (Figure 3 and Supplemental Figures 3 and 4). We observed that Signal B, tagged by the 
IL1RL1 intronic variant rs4142132, had an effect on the mRNA levels of  the transcripts encoding soluble 
and membrane IL1RL1 isoforms in HBECs cultured in vitro. The presence of  the risk (A) allele associated 
with a lower FEV1 resulted in lower levels of  both IL1RL1 mRNA isoforms (P < 0.05) (Figure 3, A and B), 
an effect mirrored in the whole lung tissue. These results were confirmed at the protein level, where levels 
of  soluble IL1RL1 in HBEC supernatants were lower in carriers of  the (A) allele (P < 0.01) (Figure 3E).
The allele associated with severe asthma at Signal C (rs17027258 [A]) was associated with elevated 
IL1RL1 mRNA levels of  the transcripts encoding transmembrane IL1RL1 but not with those encoding 
the soluble isoform in HBECs (P < 0.05) (Figure 3, C and D), in agreement with the direction of  effect 
Figure 2. Linkage disequilibrium map of the 4 IL1RL1 variants identified in Stages 1–3 and selected as SNPs for 
functional study. Figure identifies the level of linkage disequilibrium between signals identified based on r2 values. 
Image generated using the EUR population of the Phase I cohort of the 1000 genomes study via the LDmatrix tab of 
the online software tool LDlink 3.6, available at https://ldlink.nci.nih.gov/.
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observed in lung tissue. At the protein level, the risk allele (A) was associated with elevated soluble IL1RL1 
levels in cellular supernatants (Figure 3G).
In HBECs, as opposed to no effect in whole lung tissue, the asthma risk (T) allele for Signal A 
(tagged by rs995514) also associated with elevated blood eosinophil levels, resulted in a lower levels of  
soluble IL1RL1 protein, but had no effect on mRNA isoforms (Figure 3F and Supplemental Figures 3 
and 4). For Signal D (rs10192157), no effect was observed on either IL1RL1 mRNA or protein levels 
(Supplemental Figures 3 and 4).
Effect of  asthma-relevant stimuli on IL1RL1 expression. Next, we considered the possibility that disease 
state and/or relevant microenvironmental triggers may regulate IL1RL1 expression in a SNP-dependent 
fashion. Therefore, we investigated the effect of  asthma-relevant stimulations of  cultured HBECs obtained 
from asthma subjects on IL1RL1 expression in carriers and noncarriers of  phenotype-associated alleles (i.e., 
inducible eQTLs). Prior to stratification, we observed an increase in soluble IL1RL1 protein levels in cell 
supernatants following stimulation with HDM for 24 hours (P < 0.01); however, no change was observed 
with either RV-16 or with IL-33 stimulation (P > 0.05) (Figure 4, A and B). Conversely, stimulation with 
HDM reduced membrane IL1RL1 mRNA levels 3.5-fold (Figure 4C, P < 0.05), while RV-16 stimulation 
reduced soluble IL1RL1 mRNA expression 4.5-fold (Figure 4D, P < 0.05). No alterations in IL1RL1 mRNA 
were observed in response to IL-33; however, a response to IL-33 was confirmed using IL-8 mRNA levels 
as an outcome (Figure 4E).
IL1RL1 variation has an impact on IL1RL1 regulation in response to asthma-relevant stimuli. Stratification 
based on our 4 selected signals identified that HDM-driven effects on IL1RL1 expression were genotype 
dependent, with effects observed for all 4 selected SNPs (Figure 5 A–D, Supplemental Figures 5 and 6).
In Signal A (tagged by rs995514), there was a modest increase in the level of  soluble IL1RL1 pro-
tein (1.63-fold) in the presence of  the asthma protective allele (C) (Figure 5A). In Signal C (tagged by 
rs17027258), presence of  the severe asthma risk allele (A) identified modest elevation in IL1RL1 soluble 
protein expression after HDM stimulation (1.5-fold; P < 0.01) (Figure 5B). The largest response to HDM 
was observed in the functionally relevant TIR domain haplotype (Signal D [tagged by rs10192157]). Here, 
the presence of  the protective allele (T) was associated with a 2-fold increase in soluble IL1RL1 protein 
after HDM stimulation (Figure 5C). No effect was observed on IL-33 stimulation (Supplemental Figure 5).
At the mRNA level, no apparent effects were observed for Signals A, C, and D, in contrast to the 
observed effects at the protein level (Supplemental Figure 6). However, in Signal B, total IL1RL1 mRNA 
expression was reduced (31.73-fold) in response to HDM but only in cells carrying the allele (G) associated 
with higher lung function (FEV1) (Signal B, Figure 5D, P < 0.05). However, it is important to note that the 
baseline levels of  total IL1RL1 mRNA in GG carriers were significantly higher than that for both AA and 
AG genotype carriers, in keeping with the findings reported above (Figure 3, A and B).
IL1RL1 coding region variants associated with asthma influence signaling. We next tested functional effects 
of  the membrane IL1RL1 TIR domain haplotype that are tagged by Signal D. These haplotypes encode 
IL1RL1 proteins that present with a 4–amino acid change in the intracellular TIR signaling domain (Ala-
433Thr/Gln501Arg/Thr549Ile/Leu551Ser) (12). The potential functional effects include the following: (a) 
IL1RL1-b coding region variants determine the magnitude of  signaling response downstream of  IL-33 (23) 
Table 1. Summary of 3 selected variants identified in our association analyses and selected for stratification of functional work
SNP Position Gene C/NC MAF Phenotype Cohort Effect FDR
rs12474258A 
(Signal A)
2:102816695 IL1RL2 T/C 0.40 (C) Asthma Blood 
Eosinophil 
LevelsA
LifeLines + + 0.0399 0.0175
rs4142132A 
(Signal B)
2:102937482 IL1RL1 A/G 0.49 (A) FEV1 GASP + DAG – 0.0291
rs72825929 
(Signal C)
2:103087086 3′ IL18RAP A/G 0.10 (G) Severe Asthma NGS + 0.0351
MAF, Minor allele frequency in the EUR population; LD, linkage disequilibrium. C, coded allele; NC, noncoded allele. Ars12474258 shows limited LD (r2 = 
0.1) with previously reported asthma associated SNP rs13431828 (C) (5, 57, 58), while rs4142132 shows LD (r2 = 0.54) with the previously reported asthma 
associated SNP rs1420101 (A) (20, 59).
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and (b) IL1RL1 haplotypes determine the antiinflammatory effects of  anti–IL-33 and anti-IL1RL1 monoclo-
nal antibodies (23). A reductionist recombinant cell line model with a fixed genetic background was used to 
facilitate these analyses. HEK-Blue-SEAP cells transfected with empty vector or 1 of  the 2 IL1RL1 mRNAs 
encoding the alternative TIR domain IL1RL1 proteins, which demonstrated the same capacity to signal via 
NF-κB following TNF-α stimulation (Figure 6A). Escalating doses of  recombinant IL-33 were able to induce 
NF-κB signaling, in a dose dependent manner, in the 2 cells lines containing the IL1RL1 protein (Figure 6B). 
Cells carrying the asthma risk haplotype (Ala433/Gln501/Thr549/Leu551) tagged by the Signal D SNP 
rs10192157 (CC) demonstrated a 2.9-fold induction at the highest dose of  IL-33 (50 ng/mL) in this cell sys-
tem, which was significantly higher than the modest activity observed for the asthma protective TIR domain 
haplotype protein (Thr433/Arg501/Ile549/Ser551) (1.3-fold) (Figure 6B). Additionally, cells carrying the 
asthma risk haplotype and stimulated with 50 ng/mL IL-33 were more amenable to the antiinflammatory 
effects of  blocking either IL1RL1 or IL-33 using monoclonal antibodies compared with the alternative hap-
lotype, where blocking antibodies had a minimal effect on reducing NF-κB signaling (Figure 6, C and D).
IL1RL1 coding region variants associated with asthma do not modify TLR signaling. IL1RL1 signaling is 
thought to modify TLR-2 and -4 activation (15, 16); therefore, we hypothesized that the IL1RL1 TIR domain 
haplotype variation may influence this relationship. For these experiments, we used ILR1L1 overexpression 
vectors in transfected cells whose functionality was confirmed by the capacity to induce ERK1/2 activa-
tion after IL-33 exposure (Supplemental Figure 7). We did not observe an effect of  overexpression of  the 2 
different IL1RL1 exon 11 haplotypes on the sensitivity of  HEK-Blue cells to TLR2-induced NF-κB activity 
after stimulation using a dilution series of  Pam3Cys (Supplemental Figure 8A). We also did not observe an 
IL1RL1 exon 11 haplotype–driven effect on TLR4-induced NF-κB activity in HEK-Blue cells after stimu-
lation with a dilution series of  LPS (Supplemental Figure 8B). These studies show that, while the IL1RL1 
exon 11 haplotype regulates sensitivity to IL-33 (Figure 6), the proposed regulatory function of  IL1RL1-b 
on TLR2 or TLR4 signaling (15, 16) could not be confirmed (Supplemental Figure 8).
Bioinformatic analyses of  prioritized signals using ENCODE. We investigated each signal including SNPs 
in LD defined by r2 > 0.8 for potential functional effects using the Encyclopaedia of  DNA Elements 
(ENCODE) resource via HaploReg (Supplemental Table 9). Two of  the investigated LD blocks tagged by 
Signals A and B (rs12474258 and rs4142132) were found to have multiple SNPs positioned in enhancer 
histone mark sites, with DNase hypersensitivity sites also identified within the Signal B region (rs4142132), 
a region where protein binding consensus sequences exist and affect regulatory motifs. Motifs changed 
in Signals A and B included cell type–specific transcription factors such as GATA-2, active in mast cells 
and basophils (24) and positively regulating IL1RL1 expression (25), and FOXA1/2, active in HBECs 
(26). Similarly, the functional SNP rs10192157 (Signal D) altered Gfi1 transcription factors linked to type 
2 inflammation and a regulator of  IL1RL1 expression (27). There was also generic activation–induced 
transcription factors such as Fos/Jun (AP-1), NF-κB, and cEBP/p300 found to be bound to these motifs. 
Table 2. Proxies for the 4 investigated signals used for the functional analyses presented in this manuscript






















Signal A rs12474258 T/C T Not 
applicable
– – – – rs995514 T/C T 0.40 (C) 0.325A
Signal B rs4142132 A/G A rs1420088 C/T C 0.49 (C) 1.00 Not 
applicable
– – – –
Signal C rs72825929 A/G A rs11690532 C/T C 0.17 (T) 0.536 rs17027258 A/G A 0.10 (G) 0.311B
Signal D rs10192157 C/T C Not 
applicable
– – – – Not 
applicable
– – – –
Proxies were utilized for the 3 SNPs associated with asthma-related phenotypes in the whole lung and/or the epithelial eQTL data sets due to the lack of 
genotyping of the original tagging SNP in these data sets. Selected proxies were SNPs presenting with the highest r2 value within the data set. The fourth signal 
(D) is the TIR homology domain variant selected for follow-up. AAlthough presenting with a moderately low r2 value, rs995514 was considered an appropriate 
proxy due to its stronger LD (r2 = 0.45, EUR) with rs3917243, another SNP within the association region that identified rs12474258. BAlthough presenting with 
a moderately low r2 value, this SNP was also identified (FDR < 0.05) as being associated with severe asthma in the resequencing data set. MAF, minor allele 
frequency. Proxies utilized in the bronchial epithelial brush eQTL have not been included in this table, as no association was reported in this eQTL data set.
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This highlights potential functional effects for 3 of  our 4 selected signals of  association on both cell type–
specific and ubiquitous regulation of  IL1RL1 expression (Supplemental Table 9). No SNPs were identified 
to be in LD for Signal C (rs72825929), and no enhancer histone mark sites, DNase hypersensitivity, or 
protein motif  binding were identified for this SNP. However, rs72825929 modifies the Sox (sex-determining 
region Y [Sry] box–containing) family of  transcriptional factors, which have been shown to be involved in 
lung organogenesis, with Sox2 in particular playing a crucial role in the proliferation and differentiation 
of  respiratory epithelial, trachea, airway branching, and Clara cells (28).
Discussion
Main findings. We set out to extend our understanding of  the IL1RL1 locus in asthma, one of  the most 
reproducible association signals identified to date, with a particular focus to the contribution of  the IL1RL1 
gene. We provide insight into the nature of  the genetic association with clinical and immunological features 
of  asthma and the mechanistic underpinnings of  these associations with respect to IL1RL1 expression 
and activity. In this multiple-cohort study, we extend a priori evidence that genetic variation in the IL1RL1 
region is important for asthma susceptibility and blood eosinophil counts. In particular, we identify that 
a functional haplotype consisting of  several polymorphisms encoding 4 amino acid changes (increased 
asthma risk, Ala433/Gln501/Thr549/Leu551) and present in ~50% of  the European population enhanced 
NF-κB activity after IL-33 stimulation. This has potentially important implications for targeted asthma 
therapies, where expression of  the risk haplotype could influence therapeutic efficacy. Functional analyses 
demonstrated that 3 of  our 4 independent signals of  association, Signals B, C, and D — tagged by SNPS 
rs4142132, rs72825929, and rs10192157 — are eQTLs for IL1RL1 in lung tissue. These regulatory roles 
were retained in cultured primary HBECs at both the mRNA and protein levels. Interestingly, although 
not an eQTL in the whole lung data set, Signal A (rs12474258) was an eQTL in cultured BECs for soluble 
IL1RL1 protein. Thus, our data suggest cell type specificity of  eQTL for IL1RL1, suggesting that specific 
subtypes of  asthma may be driven by different cell types in different patients. Therefore, different asthma 
subtypes may be compartment specific, where specific cell types such as lung structural, inflammatory, and 
isolated immature basal epithelial cells may predominate.
Interestingly, there was a lack of  eQTL effects observed in bronchial biopsies and bronchial brushes tak-
en from controls without respiratory diseases, while we did observe eQTLs in cultured primary HBECs of  
asthma patients, compatible with the context dependency of  eQTLs. We therefore investigated whether the 
selected SNPs act in such a context-dependent manner (i.e., inducible eQTLs), through functional studies. 
We identified that all of  our signals of  interest were able to modulate response to HDM, a common allergen 
associated with asthma and allergies, on IL1RL1 expression in HBECs. These data provide a potential link 
Table 3. Expression quantitative trait loci (eQTL) analysis for signals (tagging SNPs or proxies) in a data set for human lung tissue
  Soluble and membrane 
IL1RL1  
X100148210_TGI_at
Soluble IL1RL1  
X100148162_TGI_at
Soluble IL1RL1  
X100312840_TGI_at
Membrane IL1RL1  
X100302151_TGI_at
Signal/SNP C/NC Risk 
allele
MAF β SE P β SE P β SE P β SE P
Signal A 
rs12474258
C/T T 0.36 
(C)
–0.01 0.05 8.36 × 
10–1
–0.01 0.04 7.38 × 
10–1
–0.03 0.04 4.58 × 
10–1




T/C C 0.49 
(C)
0.96 0.04 4.88 × 
10–137
0.78 0.03 8.87 × 
10–148
0.74 0.03 6.09 × 
10–150




C/T C 0.17 (T) 0.55 0.06 2.03 × 
10–23
0.41 0.04 1.73 × 
10–20
0.38 0.04 1.75 × 
10–20
0.045 0.01 1.17 × 
10–3
Signal D  
rs10192157
T/C C 0.40 
(T)
0.20 0.05 5.62 × 
10–5
0.13 0.04 1.11 × 
10–3
0.15 0.04 3.55 × 
10–5
0.004 0.01 7.49 × 
10–1
These analyses identified eQTLs for SNPs rs1420088 and rs11690532 with both membrane and soluble IL1RL1. The coded allele for Signal B, protective 
against decline in lung function [FEV1] and the coded asthma risk allele for Signal C were both associated with elevations in gene expression in the whole 
lung. The structural variant rs10192157 is only an eQTL for the soluble isoform of IL1RL1 with the asthma risk allele (noncoded) associated with lower levels 
of soluble IL1RL1. C, coded allele; NC, noncoded allele. Ars1420088 was used as a proxy for rs4142132 (r2 = 1.0, EUR). Brs11690532 was used as a proxy for 
rs72825929 (r2 = 0.54, EUR), MAF, minor allele frequency.
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between IL1RL1 genetic variants and IL1RL1 regulation of  IL-33 inflammation in HDM-induced type 2 
immune responses in the lung, where the IL-33/IL1RL1 axis has been shown to be involved (29, 30). Final-
ly, we also investigated IL1RL1 coding region variation and established that cells carrying the IL1RL1 TIR 
domain asthma risk haplotype (Signal D) presented with an exaggerated inflammatory response to IL-33 
Figure 3. Baseline IL1RL1 mRNA and soluble IL1RL1 protein levels are driven by SNPs in cultured human bronchial epithelial cells. (A and B) In cultured 
HBECs, the lower level of IL1RL1 soluble and transmembrane mRNA can be observed in carriers of the risk allele (A) for lower lung function (FEV1) for Signal B 
(rs4142132; A [AA, n = 6; AG, n = 11; GG, n = 12] and B [AA, n = 7; AG, n = 11; GG, n = 12]; P < 0.05). (C and D) Increased levels of total and transmembrane IL1RL1 
mRNA was observed for carriers of the asthma risk allele (A) in Signal C (rs17027258, proxy for rs72825929; C [AA, n = 17; AG/GG, n = 10] and D [AA, n = 19; AG/GG, 
n = 12]; P < 0.05). (E–G) Changes in mRNA levels were reflected in soluble IL1RL1 protein levels in matched cellular supernatants (F [TT, n = 7; TC, n = 10; CC, n = 11] 
and G [AA, n = 16; AG/GG, n = 12]; P < 0.05); in Signal A, carriers of the asthma risk/elevated blood eosinophil levels allele of SNP rs995514 (proxy for rs12474258) 
(T) presented with lower levels of IL1RL1 soluble protein (E [TT, n = 4; TC, n = 13; CC, n = 11]; P = 0.002). However, this was not observed at the RNA level (Supple-
mental Figure 3). Statistics were run using Mann-Whitney U test (C, D, and G) or Kruskal-Wallis test (A, B, E, and F), as relevant. Data are represented by Tukey 
box and whisker plots, where the box covers data from the 25th to the 75th percentiles, with the center line denoting the median of the data. Whisker plots 
identify the interquartile range as determined by the Tukey method, with resulting outlier data displayed as distinct points outside the whiskers.
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that is more amenable to the antiinflammatory effects of  either anti–IL-33 or anti-IL1RL1 monoclonal anti-
bodies. This has implications for the targeting of  the IL-33/IL1RL1 axis inhibitors to a subset of  patients of  
a specific genotype likely to gain the greatest clinical benefit and is highly relevant, with multiple pharmaceu-
tical companies developing anti–IL-33/IL1RL1 approaches for the treatment of  asthma.
Genetic associations. The locus on chromosome 2q12, which includes the IL1RL1 gene, has shown a 
significant replicated association with asthma (5, 7, 18, 20, 22) or asthma-relevant traits such as childhood 
asthma (21, 31, 32), childhood asthma with exacerbation (31), severe asthma (33, 34), asthma with hay 
fever (35), type 2 inflammation in asthma (36), and blood eosinophil counts (20). Sentinel SNPs identified 
in these association studies span the 2q12 region, covering multiple genes, with evidence based on linkage 
disequilibrium pointing to independent association signals (20).
In order to characterize further the contribution of  genetic variants to features of  asthma, we carried 
out association testing across the Lifelines/GASP/DAG/MAAS cohorts. This identified that chromosome 
2q12 region variation is associated with blood eosinophil numbers (Signal A) and lung function (FEV1) 
(Signal B). We also investigated SNPs previously associated with asthma or asthma-related traits in the 
region, with 2 of  these SNPs, rs13431828 and rs10173081, being associated with asthma diagnosis in our 
Lifelines analysis (Supplemental Table 2). We also confirmed phenotypic overlap between asthma and blood 
eosinophil counts in Signal A by investigating 19 SNPs, previously associated with asthma, in this region in 
LD with Signal A. Significant overlap between these SNPs and SNPs associated with eosinophilia counts 
in our cohorts and in the literature was observed (Supplemental Table 8). To complement the investigation 
Figure 4. Asthma relevant microenvironments modulate IL1RL1 mRNA levels and soluble IL1RL1 protein levels in bronchial epithelial cells isolated 
from asthma patients and cultured in vitro. (A) Stimulation of cells with 50 μg/mL house dust mite (HDM) for 24 hours resulted in increased release of 
soluble IL1RL1 into the cellular supernatant (P = 0.003, n = 18). (B) RV-16 (MOI: 1) stimulation for 24 hours did not significantly influence IL1RL1 protein 
release in the cell supernatants (P = 0.05, n = 18). (C and D) HDM stimulation resulted in a 3.5-fold reduction of membrane IL1RL1 mRNA (C) (P = 0.045, n = 
15), while stimulation with RV-16 (MOI: 1) for 24 hours reduced soluble IL1RL1 mRNA levels 4.4-fold (D) (P = 0.022, n = 15). (E) IL-33 stimulation did not alter 
IL1RL1 protein or mRNA levels; however, it did induce IL-8 mRNA, demonstrating cell activation (P = 0.039, n = 18). Statistics were run using Mann-Whit-
ney U test (B–E) or Kruskal-Wallis test (A), as relevant to the data. Data are represented by Tukey box and whisker plots, where the box covers data from 
the 25th to the 75th percentiles, with the center line denoting the median of the data. Whisker plots identify the interquartile range as determined by the 
Tukey method, with resulting outlier data displayed as distinct points outside the whiskers.
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of  the genetic architecture of  the locus, we completed next-generation sequencing analyses and identified 
4107 variants spanning the region, of  which 3 met criteria for association with severe asthma in case/con-
trol analyses (FDR < 0.05) and survived quality control, including sentinel variant rs72825929 (A/G [5′ to 
SLC9A4]), Signal C. Although limited by small population numbers and pooled analysis, additional support 
for the association of  Signal C with asthma was determined through previously published GWAS, where 
association was shown with all asthma (rs11690532) (5) and pulmonary function (rs17027258/rs11690532; 
FEV1 and FEV1/FVC) (37). More importantly, Signal C was also associated with moderate-to-severe asthma 
in the largest GWAS of  this phenotype published to date, to our knowledge (rs72825929; β: 0.11, P = 0.0016, 
Allele A) (33). In Lifelines, rs72825929 was associated with blood eosinophil counts in the general popu-
lation ([G] β: 0.05, SE: 0.015, FDR: 0.03, AF general population [G]: 0.10) but not with the other studied 
phenotypes. Based on these analyses, we selected 3 SNPs that identify key signals of  association spanning 
the region for functional analyses and also included TIR domain SNP rs10192157 (Signal D) from the lit-
erature, giving a total of  4 signals for functional follow-up. Overall, these data complement and extend the 
accumulating data, suggesting a role for the IL-33/IL1RL1 axis that is genetically determined in T2-driven 
inflammation (36, 38) and eosinophilic asthma (20). Taken together, our data suggest that there are multiple 
independent genetic signals in the IL1RL1 locus that may be particularly important in driving severe, eosino-
philic asthma phenotype with reduced lung function, with limited evidence for genetic variants driving other 
features of  asthma such as atopy, total IgE levels, and age at onset in these cohorts.
eQTLs. Previous work has established that genetic variation in the IL1RL1 locus can act as eQTLs for 
IL1RL1 mRNA, as methylation QTLs in WBCs and as protein QTL (pQTL) for serum levels of  soluble 
IL1RL1 (13, 21, 23, 38–40). In this study, we specifically investigated the functional effects of  our 4 priori-
ty signals in (a) lung tissue, (b) airway epithelial brush samples, and (c) cultured HBECs at baseline and in 
Figure 5. SNPs regulate IL1RL1 mRNA and protein expression levels in response to asthma-relevant microenvironments. (A–C) Increased release of IL1RL1 
protein in response to HDM was present in 3 of our 4 selected signals: Signal A (rs995514; proxy for rs12474258) for the protective allele for asthma and ele-
vated blood eosinophils (C) (P < 0.05), Signal C (rs17027258; proxy for rs72825929) risk allele for severe asthma (A) (P < 0.01), and Signal D (rs10192157) for the 
protective allele for asthma (T) (P < 0.05) (A [CC, n = 8; TC/TT, n = 8], B [AA, n = 11; AG/GG, n = 5], and C [CC, n = 8; TC/TT, n = 10], respectively). (D) Decreased 
levels of total IL1RL1 mRNA in response to HDM is present only in Signal B (rs4142132) for carriers of the allele protective for reductions in lung function (FEV1) 
(G) (AA, n = 4; AG, n = 5; GG, n = 4; P < 0.05). Statistics were run using a Kruskal-Wallis test. Data are represented by Tukey box and whisker plots, where the 
box covers data from the 25th to the 75th percentiles, with the center line denoting the median of the data. Whisker plots identify the interquartile range as 
determined by the Tukey method, with resulting outlier data displayed as distinct points outside the whiskers.
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the presence of  asthma-relevant stimuli. Lung tissue eQTL identified 3 of  the 4 selected signals as eQTLs 
for IL1RL1, with differential SNP effects observed for membrane and soluble isoforms. Interestingly, the 
presence of  the asthma risk allele for the 2 asthma selected IL1RL1 signals (Signals A and C) presented 
with contradictory effects of  IL1RL1 mRNA transcripts in lung tissue, suggesting that these 2 independent 
signals may have different roles/functionality with regard to IL1RL1 and asthma. The effect size of  the 
associations was greatest for the soluble IL1RL1 mRNA, suggesting that IL1RL1 eQTL effects are more 
Figure 6. Functional analyses of the IL1RL1 TIR risk haplotype in an in vitro reductionist model identifies an exaggerated response to IL-33 that is 
more amenable to anti–IL-33/IL1RL1 treatment. Transient transfection of HEK–NF-κB–SEAP reporter cells with IL1RL1 containing the 2 TIR domain 
polymorphism haplotypes provides a platform to identify differential NF-κB signaling. (A) Cells transfected with empty vector, IL1RL1 containing the 
asthma risk haplotype (Ala433/Gln501/Thr549/Leu551), or IL1RL1 containing the protective haplotype (Thr433/Arg501/Ile549/Ser551) have the same 
capacity to signal via the NF-κB pathways in response to 10 ng/mL TNF-α. (B) The presence of the IL1RL1 receptor carrying the asthma risk haplotype 
identified a 2-fold and 3-fold increase in signaling on stimulation with 10 ng/mL and 50 ng/mL of human recombinant IL-33, respectively, whereas an 
attenuated response was observed in the protective haplotype. (C) The response induced by 50 ng/mL IL-33 in the risk haplotype was amenable to 
blocking using either 10 μg/mL anti–IL-33 or anti-IL1RL1 leading to an antiinflammatory effect. (D) The effect of blocking IL-33 induced inflammation 
by anti–IL-33 or anti-IL1RL1 was minimal in carriers of the protective TIR domain haplotype. *P < 0.05, **P < 0.01, ****P < 0.0001. n = 3 for all experi-
ments. Statistics were run using a Kruskal-Wallis test. Data are represented by Tukey box and whisker plots, where the box covers data from the 25th 
to the 75th percentiles, with the center line denoting the median of the data. Whisker plots identify the interquartile range as determined by the Tukey 
method, with resulting outlier data displayed as distinct points outside the whiskers.
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likely to translate to functional effects through regulation of  soluble rather than membrane IL1RL1 levels, 
with the exception of  the TIR domain–effecting SNP rs10192157 (Signal D). This latter SNP has also 
been identified as an eQTL for IL1RL1 in nonstructural cells (41). Our data are in good agreement with 
the lung eQTL data found in the GTEx database (https://gtexportal.org/home/) (42). However, when 
comparing our 3 eQTL signals with the strongest IL1RL1 eQTL signals in this data set, a near-perfect 
LD pattern (r2 ≥ 0.98) was only observed for Signal B, which may suggest that the other 2 eQTL signals 
(Signals C and D) may be LD shadows of  the true causative eQTL variant. On the other hand, our data 
are further supported by being in good agreement with previous work examining genetic variants that are 
associated with soluble IL1RL1 mRNA (36) and serum levels of  soluble IL1RL1 (23). More specifically, 
Signals A–D have all recently been associated with plasma IL1RL1 levels (43). Searching for our 4 signals 
on Open target genetics (https://genetics.opentargets.org/, accessed June 18, 2019), we identified that the 
risk allele in Signal A (T) was associated with elevated IL1RL1 levels in blood plasma (β: -0.202; P = 8.3 
× 10–16), which contrasts to the lack of  eQTL reported in our lung and biopsy/brush eQTL data sets. The 
remaining eQTLs in plasma extracted from whole blood provided additional insight (e.g., the risk allele 
for Signal B [A] was associated with lower levels of  plasma IL1RL1 [rs10179654, β: –0.85, P = 3.00 × 
10–391]) (43), which supports our findings and the concept that blood levels of  soluble ST2 may be driven 
by epithelial produced protein (36). The risk allele for Signal C (A) was associated with elevated levels 
(β: –0.469, P = 5.5 × 10–34), and the risk allele of  Signal D (C) was associated with lower levels of  IL1RL1 
(β: –0.288, P = 1.7 × 10–30) in good agreement with our data across data sets.
Importantly, our data extend this work by offering a comprehensive analysis of  all IL1RL1 transcripts 
(total, membrane, and soluble IL1RL1 encoding mRNA) and extends the recently suggested concept that 
asthma risk alleles essentially lead to a decrease in soluble IL1RL1, and this lack of  decoy receptor dimin-
ishes the ability to mitigate the effects of  IL-33 (36). Importantly, these analyses highlight multiple signals 
spanning the IL1RL1 locus that can regulate IL1RL1 and contribute to disease mechanisms via modula-
tion of  IL1RL1 receptor levels.
We did not observe SNP eQTL effects in the biopsy and bronchial brush data sets generated from tissue 
samples obtained from volunteers without respiratory diseases, which is in contrast to a recent study that identi-
fied 3 IL1RL1 SNPs (rs12712135; tagged by Signal B; rs1420088 [r2 = 0.98], rs1041973 and rs10185897), which 
showed association with membrane IL1RL1 mRNA in bronchial brush samples from asthma patients (38). This 
can potentially be explained due to differences in sample cell composition and by the fact that the eQTL was 
run in a nonasthmatic population in our analyses, which would indicate that the eQTL effects are disease spe-
cific. To provide greater insight, we therefore completed reductionist eQTL analyses in cultured HBECs isolated 
from asthma patients. Here, we confirmed the signals tagged by Signals B and C (rs4142132 and rs72825929) as 
eQTLs, where the observed direction of effect for both signals complemented those seen in our lung tissue data 
base. Interestingly, we demonstrated that the asthma protective allele (C) for Signal A (rs995514) was an eQTL 
in cultured epithelial cells, being associated with elevation in soluble protein levels. In contrast, no eQTL 
could be identified for Signal D (rs10192157). These data provide an additional indication that IL1RL1 
SNPs act as an eQTL in a tissue- and cell type–specific manner, potentially with inflammatory cells contribut-
ing to the lung tissue findings (e.g., mast cells, basophils, Th2 cells, ILC2s, and eosinophils). These data do not 
support the hypothesis that presence of asthma risk alleles leads to reduced soluble IL1RL1 to act as a decoy, 
limiting the mitigation of the biological effects of IL-33; however, they do suggest a complex effect of genetic 
signals on membrane and soluble IL1RL1 levels that is cell, tissue, and context dependent. For example, we 
hypothesize that changes in the IL1RL1 TIR signaling domain structure, — driven by the variation in Signal D, 
which we have shown drives increased receptor signaling — may cause a negative feedback loop that attenuates 
IL1RL1 and concurrent soluble IL1RL1 expression.
Inducible eQTLs. We tested for inducible eQTLs of  our priority signals by culturing HBECs in the pres-
ence and absence of  RV-16, HDM, and human recombinant IL-33. In general, RV-16–stimulated HBECs 
showed a decrease in soluble IL1RL1 mRNA; however, no SNP-specific effects were observed, suggesting a 
limited role of  these eQTLs in regulating RV-16–driven effects on soluble IL1RL1 mRNA.
When considering the aeroallergen HDM, another relevant environmental agent involved in aller-
gic asthma, our data identified that HBECs release soluble IL1RL1 in response to HDM; however, this 
response was accompanied by a decrease in membrane IL1RL1 mRNA. This is especially relevant when 
considering that elevations of  circulating IL-33 on HDM stimulation have been reported in mouse models 
(44, 45), with attenuated HDM-induced airway hyperresponsiveness in IL1RL1-KO mice. We therefore 
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suggest that a negative feedback mechanism may exist in HBECs, where attenuation of  membrane receptor 
expression may act as a measure to halt HDM-induced activation of  Th2 inflammation.
Stratification of  these observations based on genetic signals identified that this mechanism appears 
to be SNP dependent. Carriers of  the asthma protective allele in Signal A (rs995514; CC) and Signal D 
(rs10192157; TC/TT) responded to HDM through elevations in soluble IL1RL1 protein. This observation 
ties in well with the hypothesis that increased levels of  circulating soluble IL1RL1 protein may act as a decoy 
receptor for circulating IL-33, preventing activation of  the transmembrane receptor and relates to our earlier 
observation that asthma risk allele carriers for IL1RL1 variants present with lower soluble IL1RL1 protein. 
However, homozygote carriers of  the asthma risk allele in Signal C (rs17027258; AA) also presented elevat-
ed levels of  soluble IL1RL1 protein following HDM stimulation, suggesting potential roles of  circulating 
soluble IL1RL1 that may induce asthma under certain conditions.
SNP stratification of  IL1RL1 expression at the mRNA level following HDM stimulation suggests that 
Signal B (rs4142132) is crucial in driving the attenuation of  IL1RL1 expression identified in the nongeno-
type selected experiments, as it was the only region to act as an eQTL in this regard. This effect appears to 
be driven by the eQTL effects at baseline, where sufficient IL1RL1 levels for a negative feedback mechanism 
are only present in carriers of  the protective allele.
Considering these findings in relation to IL1RL1 inducible eQTLs, we present the signals at Signal B 
(rs4142132) and Signal C (rs72825929) as signals of particular importance for IL1RL1 regulation both at base-
line in cultured epithelial cells and in response to these allergic triggers. The Signal at position B (rs4142132) is 
associated with blood eosinophils, childhood asthma, atopy, type 2 inflammation, and asthma (20, 36), all rele-
vant to allergic disease potentially driven by allergens such as HDM, whereas the Signal C (rs72825929) is asso-
ciated with general allergic disease (4) and therefore also potentially has relevance to allergens such as HDM.
Interestingly, ENCODE data indicate that the effect on transcription factor motif  binding for Signal C 
(rs72825929) is minimal, with an effect only on the Sox family of  transcription factors, which have been 
linked with the normal development of  the trachea and the lung (46–48). However, a greater number of  
motif  changes disrupted by the remaining 3 polymorphisms, with significant overlap, can be observed. 
These include GATA binding motifs, where GATA2 is shown to regulate IL1RL1 expression in mast cells 
and basophils (25) and has been shown to mediate the effects of  HDM in the human lung (49). Of  note 
also is that several of  the eQTL SNPs resulted in changes in type 2 inflammatory transcription factors that 
are known to regulate IL1RL1 (e.g., Gfi1). However, a large range of  ubiquitously expressed transcription 
factors indicates that the effect on IL1RL1 expression by different stimuli may be driven through different 
transcription factor binding motif  interactions. While we present a comprehensive analysis of  functional 
effects of  IL1RL1 region SNPs for IL1RL1 gene expression and function, we acknowledge that functional 
effects on other genes ( eQTL effects on IL18R1, for example) may be of  relevance, as well; however, these 
were beyond the focus of  our current investigations to advance our understanding of  the contribution of  
genetic variants to IL1RL1 biology in the context of  asthma.
Coding variants. Finally, we examined the functional effects of  the rs10192157 SNP that is in com-
plete LD with several polymorphisms encoding 4 amino acid changes: Ala433/Gln501/Thr549/
Leu551 being the asthma risk haplotype and Thr433/Arg501/Ile549/Ser551 being the protective hap-
lotype. In agreement with other reports, we show that the asthma risk haplotype leads to enhanced 
NF-κB activity after IL-33–mediated IL1RL1 signaling in a reductionist cell model (18, 23). It has been 
previously suggested that IL1RL1 may also affect TLR2 and TLR4 signaling (16), but we were unable 
to show supporting evidence for this in vitro. However, we do show that cells carrying the asthma risk 
IL1RL1 protein are more amenable to the antiinflammatory effects of  anti-IL1RL1 and anti–IL-33, 
which has important therapeutic implications for potential stratified medicine approaches, especially in 
light of  current pharmaceutical development of  an IL-33/IL1RL1 antagonist for use in asthma.
Conclusion. This study has significantly advanced our understanding of  both the phenotypic and 
the functional effects of  polymorphisms in the IL1RL1 locus in the context of  asthma (Table 4). We 
have confirmed and extended genetic association to specific features of  asthma, identifying 3 inde-
pendent signals associated with blood eosinophil counts/asthma, lung function (FEV1), and severe 
asthma. Importantly, we have extended our understanding of  Signal C (tagged by rs72825929), a 
previously reported signal for allergy (4) and self-reported asthma (50), associating it specifically to 
severe asthma. All 4 of  the signals identified for functional analyses show effects on IL1RL1 regu-
lation, complementing and extending the literature, particularly by examining eQTLs in lung tissue 
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and HBECs under different environments. However, some caveats in the data are observed — in 
particular, that asthma risk alleles at different signals have opposing effects on IL1RL1 expression, 
although this is supported by other studies and potentially highlights the complexity of  this locus. 
Overall, these data suggest that asthma and asthma phenotype–related risk alleles, as part of  distinct 
genetic signals at the IL1RL1 locus, significantly affect IL1RL1 mRNA and protein levels in a tissue- 
and isoform-specific way. Overall, our study therefore highlights the complexity of  this susceptibility 
locus for asthma and identifies multiple signal-driven mechanisms that contribute to the genetic asso-
ciation signals, which, at least in part, explains why this locus represents one of  the most reproduc-
ible association signals in asthma, to date.
Methods
Supplemental Methods are available online with this article.
Selection of genetic region and IL1RL1 SNPs
Selection of  region. For the phenotypic analyses, we selected SNPs with a MAF ≥ 0.01 located in the genomic 
region 400 kb up- and downstream the IL1RL1 gene (chr2: 102,527,961–103,368,497), which encompasses 
all of  the previously described asthma signals, as well as several additional genes (Supplemental Figure 1). 
There were 3148 and 3048 SNPs with SNPTEST infoscore > 0.3 present in the GASP and DAG cohorts 
and 2760 SNPs with PLINK infoscore > 0.7 in Lifelines. Annotated SNP location and function was deter-
mined with the use of  HaploReg v4.1 (51). All genetic data were annotated relative to assembly GRCh37/
hg19. In the MAAS analyses, 2206 SNPs were available in the region for association testing.
Selection of  SNPs for cell-based analysis. SNPs of  interest were selected using the following criteria: (a) sig-
nificant association with asthma subtypes in our genetic association analysis (FDR < 0.05), (b) a MAF over 
10% to facilitate subsequent in vitro analysis, and (c) independence based on r2 < 0.1 (in the 1000 genomes 
CEU population; ref. 17). SNP rs10192157 was also selected due to its nature as a functional SNP within 
IL1RL1. Levels of  linkage disequilibrium were identified for SNPs at each stage of  prioritization utilizing 
the online software LDlink (52, 53) (Supplemental Figures 9 and 10). From this, SNPs were prioritized 
based on LD (LD r2 < 0.1; Figure 2) and selected for further study (Table 1). A tagging SNP was chosen 
from each key haplotype block/signal of  interest after the selection process ultimately gave 4 SNPs.
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Table identifies changes in either lung or cultured epithelial mRNA expression, except were annotated as follows: Aadditional effect of variation on 
soluble IL1RL1 protein expression in HBEC supernatants; Beffect driven by alterations in baseline expression with no difference between genotypes 
following stimulation.
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ENCODE. We used data collected by ENCODE (54, 55) to identify potential functional signifi-
cance of  the associated SNPs within HaploReg v4.1 (51, 56). The data set was last accessed on the 
April 29, 2019, at 11:30 a.m.
IL1RL1 TIR domain recombinant experiments
To examine differences in NF-κB signaling between TIR domain haplotypes after IL-33 stimulation in the 
presence and absence of  anti–IL-33 or anti-IL1RL1, we used Kruskal-Wallis test followed by Bonferroni 
post hoc test. A P < 0.05 value was considered significant. In the TLR experiments, we tested 2 potential 
functional effects of  the IL1RL1-b exon 11 haplotypes based on literature. First, we tested whether the 2 
haplotypes IL1RL1-b showed a differential suppressive effect on TLR2 and TLR4 signaling, as previously 
reported for IL1RL1-b. IL1RL1-b exon 11 risk and protective haplotypes were overexpressed in HEK-Blue 
cells sensitive to either TLR2 stimulation with Pam3Cys or TLR4 stimulation with LPS at concentrations 
of  0, 0.1, 1.0, and 10 ng/mL.
Statistics
We have included details of  statistical tests and criteria used in each analysis in the online supplement; 
however, the following tests were used: (a) genotype-phenotype association testing (SNPTEST v2.5β or 
PLINK v1.90b6.7 with a FDR < 0.05 considered statistically significant), (b) resequencing in cases-controls 
association testing (Syzygy, P < 0.05 corrected for multiple testing [Bonferroni] was considered significant), 
(c) lung and bronchial biopsy eQTL (SNPtest v2.5β additive genetic model; for the 4 selected signals a P < 
0.002 [Bonferroni correction] was considered significant), and (d) cultured cell eQTL, 2-tailed Mann-Whit-
ney U or Kruskal-Wallis with Dunn’s correction for multiple testing; P < 0.05 was considered significant. 
IL1RL1 TIR domain recombinant experiments; Kruskal-Wallis with Dunn’s correction for multiple test-
ing; P < 0.05 was considered significant.
Study approval
The DAG and NORM cohort were approved by the Medical Ethics Committee of  the UMCG. For Life-
lines, all participants signed an informed consent form before they received an invitation for the physical 
examination. The Lifelines Cohort Study is conducted according to the principles of  the Declaration of  
Helsinki and in accordance with the UMCG research code. The Lifelines study was approved by the medi-
cal ethical committee of  the UMCG. The Lung eQTL study was approved by the ethics committees of  the 
Institut universitaire de cardiologie et de pneumologie de Québec and the UBC-Providence Health Care 
Research Institute Ethics Board for Laval and UBC, respectively. The study protocol was consistent with 
the Research Code of  the UMCG and Dutch national ethical and professional guidelines. In the AHBEC 
data set, brushes were collected under ethics REC 08/H0406/189 (University of  Leicester) and REC 08/
H0407/1 (University of  Nottingham). All participants in this study provided informed consent. GASP is 
a multicenter study under ethics GM129901; however, it also includes samples collected under local ethics 
from Nottingham (recruited 1990-2015), Belfast (recruited 2008-2009), Birmingham (2005-2014), Man-
chester (recruited 2008-2014), Southampton (recruited 2003-2014), Glasgow (recruited 2002-2014), and 
Leicester (recruited 2004-2015). All studies had appropriate local ethics approval.
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